Konishi Yoshiyuki, Muragaki Yoshihiro, Iseki Hiroshi, Mitsuhashi Norio, Okada Yoshikazu
Faculty of Advanced Techno-Surgery, Institute of Advanced Biomedical Engineering and Science, Tokyo Women's Medical University, Japan.
Neurol Med Chir (Tokyo). 2012;52(8):577-86. doi: 10.2176/nmc.52.577.
The present retrospective study evaluated the recurrence patterns after aggressive surgical removal of intracranial glioblastomas in 43 consecutive adult patients. The resection rate of the enhanced lesion on magnetic resonance imaging was 100% and 95-99% in 22 and 21 cases, respectively. All patients received postoperative fractionated radiotherapy (60 Gy in 30 fractions) with additional chemotherapy (25 cases) or vaccine therapy (18 cases). During follow-up (median 17 months), tumor recurrence was identified in 33 patients, most frequently regional within the wall of the resection cavity (20 cases). No clinical factor differed significantly between the groups of patients with regional or marginal tumor progression (N = 22) and patients with distant or multiple recurrences (N = 8). Progression-free survival did not differ significantly between these two groups (p = 0.27). However, overall survival was significantly longer (p = 0.04) in patients with regional or marginal tumor progression, and constituted 90% and 54% at 1 and 2 years after surgery, respectively, compared to 75% and 0% in patients with distant or multiple recurrences. Aggressive surgical resection and adjuvant management of intracranial glioblastoma may change its recurrence pattern. Tumor progression appears in the wall of the resection cavity or within 2 cm from its margin in approximately half of patients.
本回顾性研究评估了43例连续成年患者经积极手术切除颅内胶质母细胞瘤后的复发模式。磁共振成像上增强病变的切除率在22例和21例中分别为100%和95 - 99%。所有患者术后均接受了分次放疗(30次分割,共60 Gy),并联合化疗(25例)或疫苗治疗(18例)。在随访期间(中位时间17个月),33例患者出现肿瘤复发,最常见的是在切除腔壁内局部复发(20例)。局部或边缘性肿瘤进展患者组(N = 22)和远处或多发性复发患者组(N = 8)之间,没有临床因素存在显著差异。这两组之间的无进展生存期没有显著差异(p = 0.27)。然而,局部或边缘性肿瘤进展患者的总生存期明显更长(p = 0.04),术后1年和2年分别为9�%和54%,而远处或多发性复发患者分别为75%和0%。积极的手术切除和辅助治疗颅内胶质母细胞瘤可能会改变其复发模式。大约一半的患者肿瘤进展出现在切除腔壁或距其边缘2 cm范围内。